Literature DB >> 2592571

Monocyte-chemotactic activity of defensins from human neutrophils.

M C Territo1, T Ganz, M E Selsted, R Lehrer.   

Abstract

We investigated the monocyte-chemotactic activity of fractionated extracts of human neutrophil granules. Monocyte-chemotactic activity was found predominantly in the defensin-containing fraction of the neutrophil granules. Purified preparations of each of the three human defensins (HNP-1, HNP-2, HNP-3) were then tested. HNP-1 demonstrated significant chemotactic activity for monocytes: Peak activity was seen at HNP-1 concentrations of 5 X 10(-9) M and was 49 +/- 20% (mean +/- SE, n = 9) of that elicited by 10(-8) M FMLP. HNP-2 (peak activity at 5 X 10(-9) M) was somewhat less active, yielding 19 +/- 10% (n = 11). HNP-3 failed to demonstrate chemotactic activity. Checkerboard analysis of monocyte response to HNP-1 and HNP-2 confirmed that their activity was chemotactic rather than chemokinetic. Neutrophils demonstrated a low level of response to defensins but this reaction was primarily chemokinetic. Defensins may play a role in the recruitment of monocytes by neutrophils into inflammatory sites.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2592571      PMCID: PMC304087          DOI: 10.1172/JCI114394

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  A functional differentiation of human neutrophil granules: generation of C5a by a specific (secondary) granule product and inactivation of C5a by azurophil (primary) granule products.

Authors:  D G Wright; J I Gallin
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

2.  Skin window studies of the acute inflammatory responses of neutropenic patients.

Authors:  D C Dale; S M Wolff
Journal:  Blood       Date:  1971-08       Impact factor: 22.113

Review 3.  The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology.

Authors:  R A Lewis; K F Austen
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

4.  A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration.

Authors:  W Falk; R H Goodwin; E J Leonard
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

5.  Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response.

Authors:  J I Gallin; M P Fletcher; B E Seligmann; S Hoffstein; K Cehrs; N Mounessa
Journal:  Blood       Date:  1982-06       Impact factor: 22.113

6.  Bactericidal activity of fractionated granule contents from human polymorphonuclear leukocytes.

Authors:  M C Modrzakowski; M H Cooney; L E Martin; J K Spitznagel
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

7.  Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine.

Authors:  D M Humphrey; L M McManus; D J Hanahan; R N Pinckard
Journal:  Lab Invest       Date:  1984-01       Impact factor: 5.662

8.  Monocyte retention and migration in pulmonary inflammation. Requirement for neutrophils.

Authors:  D E Doherty; G P Downey; G S Worthen; C Haslett; P M Henson
Journal:  Lab Invest       Date:  1988-08       Impact factor: 5.662

9.  Chemotoxis of mononuclear cells.

Authors:  P A Ward
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

10.  Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor.

Authors:  S H Zigmond; J G Hirsch
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  128 in total

1.  Induction of a rat enteric defensin gene by hemorrhagic shock.

Authors:  M R Condon; A Viera; M D'Alessio; G Diamond
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Dynamic changes in neutrophil defensins during endotoxemia.

Authors:  M E Klut; B A Whalen; J C Hogg
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

3.  Antimicrobial defensin peptides of the human ocular surface.

Authors:  R J Haynes; P J Tighe; H S Dua
Journal:  Br J Ophthalmol       Date:  1999-06       Impact factor: 4.638

Review 4.  Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense.

Authors:  Manuela Dürr; Andreas Peschel
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

Review 5.  Defensins: microbicidal and cytotoxic peptides of mammalian host defense cells.

Authors:  T Ganz; A Oren; R I Lehrer
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

Review 6.  Roles of antimicrobial peptides such as defensins in innate and adaptive immunity.

Authors:  J J Oppenheim; A Biragyn; L W Kwak; D Yang
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

7.  Evaluation of the potential of starch-based biodegradable polymers in the activation of human inflammatory cells.

Authors:  A P Marques; R L Reis; J A Hunt
Journal:  J Mater Sci Mater Med       Date:  2003-02       Impact factor: 3.896

8.  Maternal serum concentrations of the chemokine CXCL10/IP-10 are elevated in acute pyelonephritis during pregnancy.

Authors:  Francesca Gotsch; Roberto Romero; Jimmy Espinoza; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Offer Erez; Nandor Gabor Than; Samuel Edwin; Moshe Mazor; Bo Hyan Yoon; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2007-10

Review 9.  Diversity in penaeidin antimicrobial peptide form and function.

Authors:  Brandon J Cuthbertson; Leesa J Deterding; Jason G Williams; Kenneth B Tomer; Kizee Etienne; Perry J Blackshear; Erika E Büllesbach; Paul S Gross
Journal:  Dev Comp Immunol       Date:  2007-08-03       Impact factor: 3.636

10.  Antimicrobial peptides and induced membrane curvature: geometry, coordination chemistry, and molecular engineering.

Authors:  Nathan W Schmidt; Gerard C L Wong
Journal:  Curr Opin Solid State Mater Sci       Date:  2013-08       Impact factor: 11.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.